<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="eliminate">
            <roleset id="eliminate.01" name="remove&#x0A;" wordnet="1">
                <roles>
                    <role n="0" descr="entity removing&#x0A;" />
                    <role n="1" descr="thing being removed&#x0A;" />
                    <role n="2" descr="removed from&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A 6-bp insertion located within O2 or between OT and O1 eliminates repression of the glpTQ promoter, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A 6-bp insertion located within O2 or between OT and O1 has eliminated repression of the glpTQ promoter, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A 6-bp insertion located within O2 or between OT and O1 will eliminate repression of the glpTQ promoter, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A 6-bp insertion which eliminated repression of the glpTQ promoter was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>A 6-bp insertion which eliminates repression of the glpTQ promoter is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>All three sites eliminated make the same high level of activation of B-Raf occurs.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>An asparagine residue within a kinase domain of the product is eliminated by a 3-bp in-frame deletion; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>An asparagine residue within a kinase domain of the product was eliminated by a 3-bp in-frame deletion; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>As illustrated in Figure 1, staurosporin (or genestein; data not shown) can not eliminate the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>As illustrated in Figure 1, staurosporin (or genestein; data not shown) does not eliminate the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>As illustrated in Figure 1, the stabilization seen with MG132 is not eliminated by staurosporin (or genestein; data not shown).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>As illustrated in Figure 1, the stabilization seen with MG132 was not eliminated by staurosporin (or genestein; data not shown).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>As illustrated in Figure 1, the stabilization seen with MG132 will not be eliminated by staurosporin (or genestein; data not shown).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>At a molar ratio of 5:1, binding can be completely eliminated (Figure 7).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>At a molar ratio of 5:1, binding is completely eliminated (Figure 7).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>At a molar ratio of 5:1, binding is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>At a molar ratio of 5:1, binding will be completely eliminated (Figure 7).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Binding of GntR to the operators has been eliminated by gluconate and also by 6-phosphogluconate at a 10-fold-higher concentration.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Binding of GntR to the operators was eliminated by gluconate and also by 6-phosphogluconate at a 10-fold-higher concentration.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Binding of GntR to the operators will be eliminated by gluconate and also by 6-phosphogluconate at a 10-fold-higher concentration.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Eliminating all three sites makes the same high level of activation of B-Raf occurs.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Eliminating any deleterious effects that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">any deleterious effects</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Exogenous H(2)O(2) is eliminated in transgenic plants by inhibition of any one of these molecules.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Exogenous H(2)O(2) was eliminated in transgenic plants by inhibition of any one of these molecules.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>For eliminating any deleterious effects that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">any deleterious effects</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>In gel shift assay, anti-ref1 antibody eliminates formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>In gel shift assay, anti-ref1 antibody has eliminated formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>In gel shift assay, anti-ref1 antibody will eliminate formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Inhibition of any one of these molecules eliminate exogenous H(2)O(2) in transgenic plants.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Inhibition of any one of these molecules eliminated exogenous H(2)O(2) in transgenic plants.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Inhibition of any one of these molecules is able to eliminate exogenous H(2)O(2) in transgenic plants.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Inhibition of any one of these molecules may eliminate exogenous H(2)O(2) in transgenic plants.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Inhibition of any one of these molecules, as may occur following caspase activation, eliminated vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Inhibition of any one of these molecules, as may occur following caspase activation, eliminates vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Inhibition of any one of these molecules, as may occur following caspase activation, has eliminated vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Inhibition of any one of these molecules, as may occur following caspase activation, is able to eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Microbe-detecting receptors activating immune cells, such as CD14, can eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Microbe-detecting receptors activating immune cells, such as CD14, eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Microbe-detecting receptors activating immune cells, such as CD14, eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Microbe-detecting receptors activating immune cells, such as CD14, is able to eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Mutation of T491 can eliminate the recognition by the anti-pT598 antibody while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Mutation of T491 eliminates the recognition by the anti-pT598 antibody while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Mutation of T491 has eliminated the recognition by the anti-pT598 antibody while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>One mutation can eliminate the BamHI site in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>One mutation eliminated the BamHI site in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>One mutation eliminates the BamHI site in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>One mutation has eliminated the BamHI site in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>One mutation would eliminate the BamHI site in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>One of the remaining three families carried a 3-bp in-frame deletion eliminating an asparagine residue within a kinase domain of the product; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>One of the remaining three families carried a 3-bp in-frame deletion that eliminated an asparagine residue within a kinase domain of the product; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>One of the remaining three families carried a 3-bp in-frame deletion that eliminates an asparagine residue within a kinase domain of the product; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>One of the remaining three families carried a 3-bp in-frame deletion which eliminated an asparagine residue within a kinase domain of the product; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, Sec incorporation is completely eliminated by these same mutations.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, Sec incorporation was completely eliminated by these same mutations.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, these same mutations can completely eliminate Sec incorporation (Lesoon et al., 1997).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, these same mutations completely eliminate Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, these same mutations completely eliminated Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>That the inhibitory phosphorylation can be eliminated is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>That the inhibitory phosphorylation has been eliminated is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>That the inhibitory phosphorylation is eliminated is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>That the inhibitory phosphorylation was eliminated is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>The BamHI site is eliminated in exon 7 by one mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>The BamHI site was eliminated in exon 7 by one mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>The pathogens are eliminated by microbe-detecting receptors activating immune cells, such as CD14.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>The pathogens were eliminated by microbe-detecting receptors activating immune cells such as CD14.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>The recognition is eliminated by mutation of T491 through the anti-pT598 antibody while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition</arg>
                    <arg n="2">the anti-pT598 antibody</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>The recognition was eliminated by mutation of T491 through the anti-pT598 antibody while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition</arg>
                    <arg n="2">the anti-pT598 antibody</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>The requirement of induction is eliminated by mutation of a new locus, galS, resulting in constitutive and ultrainduced levels of gal expression.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>The requirement of induction was eliminated by mutation of a new locus, galS, resulting in constitutive and ultrainduced levels of gal expression.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>The same high level of activation of B-Raf occurs only when all three sites were eliminated.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>They establish that inhibition of any one of these molecules, as may occur following caspase activation, can eliminate vital stem cells required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>This occurs by microbe-detecting receptors, such as CD14, that activate immune cells for eliminating the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>This occurs by microbe-detecting receptors, such as CD14, that activate immune cells to eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>To eliminate all three sites make the same high level of activation of B-Raf occurs.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>To eliminate the inhibitory phosphorylation is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>Transgenic plants expressing AtNDK1 under control of the CaMV 35S promoter exhibited tolerance to paraquat and high ability for eliminating exogenous H(2)O(2).</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>Vital stem cells are eliminated by inhibition of any one of these molecules, as may occur following caspase activation.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>Vital stem cells were eliminated by inhibition of any one of these molecules,as may occur following caspase activation.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>formation of the nCaRE-protein complex is eliminated by anti-ref1 antibody.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>formation of the nCaRE-protein complex was eliminated by anti-ref1 antibody.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>gluconate and also by 6-phosphogluconate at a 10-fold-higher concentration eliminate Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>gluconate and also by 6-phosphogluconate at a 10-fold-higher concentration eliminated Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>mutation of a new locus, galS eliminated The requirement of induction resulting in constitutive and ultrainduced levels of gal expression.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>mutation of a new locus, galS eliminates The requirement of induction resulting in constitutive and ultrainduced levels of gal expression.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>the HindIII site is eliminated by the other in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>the HindIII site was eliminated by the other in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>the other can eliminate the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>the other eliminated the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>the other eliminates the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>the other is able to eliminate the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>the other would eliminate the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>As illustrated in Figure 1, staurosporin (or genestein; data not shown) did not eliminate the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>Eliminating the inhibitory phosphorylation or mimicking activating phosphorylation sites is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>Mutation of T491 eliminated the recognition by the anti-pT598 antibody while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="EMBO" no="5">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet these same mutations completely eliminate Sec incorporation (Lesoon et al., 1997).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="EMBO" no="6">
                    <text>The same high level of activation of B-Raf occurs only when all three sites are eliminated.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="GREC" no="1">
                    <text>A 6-bp insertion located within O2 or between OT and O1 eliminated repression of the glpTQ promoter, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="GREC" no="2">
                    <text>Binding of GntR to the operators is eliminated by gluconate and also by 6-phosphogluconate at a 10-fold-higher concentration.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="GREC" no="3">
                    <text>In gel shift assay, anti-ref1 antibody eliminated formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="GREC" no="4">
                    <text>The requirement of induction can be eliminated by mutation of a new locus, galS, resulting in constitutive and ultrainduced levels of gal expression.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>One mutation eliminates the BamHI site in exon 7 and the other eliminates the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>One mutation eliminates the BamHI site in exon 7 and the other eliminates the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>One of the remaining three families carried a 3-bp in-frame deletion that would eliminate an asparagine residue within a kinase domain of the product; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                    <arg n="M-MOD">would</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>They establish that inhibition of any one of these molecules, as may occur following caspase activation, could eliminate vital stem cells required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>This occurs by microbe-detecting receptors activating immune cells to eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="MEDLINE" no="6">
                    <text>To eliminate any deleterious effects that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">any deleterious effects</arg>
                </example>
                <example src="MEDLINE" no="7">
                    <text>Transgenic plants expressing AtNDK1 under control of the CaMV 35S promoter exhibited tolerance to paraquat and high ability to eliminate exogenous H(2)O(2).</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                    <arg n="2">Transgenic plants</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A 6-bp insertion at a 10-fold-higher concentration eliminate repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A 6-bp insertion at a 10-fold-higher concentration eliminated repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A 6-bp insertion can eliminate repression of the glpTQ promoter while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A 6-bp insertion eliminated repression of the glpTQ promoter while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A 6-bp insertion eliminates repression of the glpTQ promoter while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A 6-bp insertion has eliminated repression of the glpTQ promoter while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>As illustrated in Figure 1, A 6-bp insertion can not eliminate repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>As illustrated in Figure 1, A 6-bp insertion did not eliminate repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>As illustrated in Figure 1, A 6-bp insertion does not eliminate repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>As illustrated in Figure 1, Binding of GntR to the operators is not eliminated by gluconate and also by 6-phosphogluconate.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>As illustrated in Figure 1, Binding of GntR to the operators was not eliminated by gluconate and also by 6-phosphogluconate.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>As illustrated in Figure 1, Binding of GntR to the operators will not be eliminated by gluconate and also by 6-phosphogluconate.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>As illustrated in Figure 1, Mutation of T491 can not eliminate the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>As illustrated in Figure 1, Mutation of T491 did not eliminate the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>As illustrated in Figure 1, Mutation of T491 does not eliminate the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>As illustrated in Figure 1, Sec incorporation is not eliminated by these same mutations.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>As illustrated in Figure 1, Sec incorporation was not eliminated by these same mutations.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>As illustrated in Figure 1, Sec incorporation will not be eliminated by these same mutations.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>As illustrated in Figure 1, a molar ratio of 5:1 can not eliminate binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>As illustrated in Figure 1, a molar ratio of 5:1 did not eliminate binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>As illustrated in Figure 1, a molar ratio of 5:1 does not eliminate binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>As illustrated in Figure 1, anti-ref1 antibody can not eliminate formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>As illustrated in Figure 1, anti-ref1 antibody did not eliminate formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>As illustrated in Figure 1, anti-ref1 antibody does not eliminate formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>As illustrated in Figure 1, binding is not eliminated by a molar ratio of 5:1.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>As illustrated in Figure 1, binding was not eliminated by a molar ratio of 5:1.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>As illustrated in Figure 1, binding will not be eliminated by a molar ratio of 5:1.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>As illustrated in Figure 1, formation of the nCaRE-protein complex is not eliminated by anti-ref1 antibody.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>As illustrated in Figure 1, formation of the nCaRE-protein complex was not eliminated by anti-ref1 antibody.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>As illustrated in Figure 1, formation of the nCaRE-protein complex will not be eliminated by anti-ref1 antibody.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>As illustrated in Figure 1, gluconate and also by 6-phosphogluconate can not eliminate Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>As illustrated in Figure 1, gluconate and also by 6-phosphogluconate did not eliminate Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>As illustrated in Figure 1, gluconate and also by 6-phosphogluconate does not eliminate Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>As illustrated in Figure 1, inhibition of any one of these molecules can not eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>As illustrated in Figure 1, inhibition of any one of these molecules did not eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>As illustrated in Figure 1, inhibition of any one of these molecules does not eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>As illustrated in Figure 1, microbe-detecting receptors activating immune cells can not eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>As illustrated in Figure 1, microbe-detecting receptors activating immune cells did not eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>As illustrated in Figure 1, microbe-detecting receptors activating immune cells does not eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>As illustrated in Figure 1, microbe-detecting receptors, such as CD14, that activate immune cells can not eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>As illustrated in Figure 1, microbe-detecting receptors, such as CD14, that activate immune cells did not eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>As illustrated in Figure 1, microbe-detecting receptors, such as CD14, that activate immune cells does not eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>As illustrated in Figure 1, repression of the glpTQ promoter is not eliminated by A 6-bp insertion.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>As illustrated in Figure 1, repression of the glpTQ promoter was not eliminated by A 6-bp insertion.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>As illustrated in Figure 1, repression of the glpTQ promoter will not be eliminated by A 6-bp insertion.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>As illustrated in Figure 1, the pathogens is not eliminated by microbe-detecting receptors activating immune cells.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>As illustrated in Figure 1, the pathogens is not eliminated by microbe-detecting receptors, such as CD14, that activate immune cells.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>As illustrated in Figure 1, the pathogens was not eliminated by microbe-detecting receptors activating immune cells.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>As illustrated in Figure 1, the pathogens was not eliminated by microbe-detecting receptors, such as CD14, that activate immune cells.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>As illustrated in Figure 1, the pathogens will not be eliminated by microbe-detecting receptors activating immune cells.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>As illustrated in Figure 1, the pathogens will not be eliminated by microbe-detecting receptors, such as CD14, that activate immune cells.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>As illustrated in Figure 1, the recognition by the anti-pT598 antibody is not eliminated by Mutation of T491.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>As illustrated in Figure 1, the recognition by the anti-pT598 antibody was not eliminated by Mutation of T491.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>As illustrated in Figure 1, the recognition by the anti-pT598 antibody will not be eliminated by Mutation of T491.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>As illustrated in Figure 1, these same mutations can not eliminate Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>As illustrated in Figure 1, these same mutations did not eliminate Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>As illustrated in Figure 1, these same mutations does not eliminate Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>As illustrated in Figure 1, vital stem cells is not eliminated by inhibition of any one of these molecules.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>As illustrated in Figure 1, vital stem cells was not eliminated by inhibition of any one of these molecules.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>As illustrated in Figure 1, vital stem cells will not be eliminated by inhibition of any one of these molecules.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>At A 6-bp insertion, repression of the glpTQ promoter can be completely eliminated (Figure 7).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>At A 6-bp insertion, repression of the glpTQ promoter is completely eliminated (Figure 7).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>At A 6-bp insertion, repression of the glpTQ promoter is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>At A 6-bp insertion, repression of the glpTQ promoter will be completely eliminated (Figure 7).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>At Mutation of T491, the recognition by the anti-pT598 antibody can be completely eliminated (Figure 7).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>At Mutation of T491, the recognition by the anti-pT598 antibody is completely eliminated (Figure 7).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>At Mutation of T491, the recognition by the anti-pT598 antibody is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>At Mutation of T491, the recognition by the anti-pT598 antibody will be completely eliminated (Figure 7).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>At anti-ref1 antibody, formation of the nCaRE-protein complex can be completely eliminated (Figure 7).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>At anti-ref1 antibody, formation of the nCaRE-protein complex is completely eliminated (Figure 7).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>At anti-ref1 antibody, formation of the nCaRE-protein complex is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>At anti-ref1 antibody, formation of the nCaRE-protein complex will be completely eliminated (Figure 7).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>At gluconate and also by 6-phosphogluconate, Binding of GntR to the operators can be completely eliminated (Figure 7).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>At gluconate and also by 6-phosphogluconate, Binding of GntR to the operators is completely eliminated (Figure 7).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>At gluconate and also by 6-phosphogluconate, Binding of GntR to the operators is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>At gluconate and also by 6-phosphogluconate, Binding of GntR to the operators will be completely eliminated (Figure 7).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>At inhibition of any one of these molecules, vital stem cells can be completely eliminated (Figure 7).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>At inhibition of any one of these molecules, vital stem cells is completely eliminated (Figure 7).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>At inhibition of any one of these molecules, vital stem cells is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>At inhibition of any one of these molecules, vital stem cells will be completely eliminated (Figure 7).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>At microbe-detecting receptors activating immune cells, the pathogens can be completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>At microbe-detecting receptors activating immune cells, the pathogens is completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>At microbe-detecting receptors activating immune cells, the pathogens is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>At microbe-detecting receptors activating immune cells, the pathogens will be completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>At microbe-detecting receptors, such as CD14, that activate immune cells, the pathogens can be completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>At microbe-detecting receptors, such as CD14, that activate immune cells, the pathogens is completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>At microbe-detecting receptors, such as CD14, that activate immune cells, the pathogens is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>At microbe-detecting receptors, such as CD14, that activate immune cells, the pathogens will be completely eliminated (Figure 7).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>At staurosporin (or genestein; data not shown), the stabilization seen with MG132 can be completely eliminated (Figure 7).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>At staurosporin (or genestein; data not shown), the stabilization seen with MG132 is completely eliminated (Figure 7).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>At staurosporin (or genestein; data not shown), the stabilization seen with MG132 is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>At staurosporin (or genestein; data not shown), the stabilization seen with MG132 will be completely eliminated (Figure 7).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>At these same mutations, Sec incorporation can be completely eliminated (Figure 7).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>At these same mutations, Sec incorporation is completely eliminated (Figure 7).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>At these same mutations, Sec incorporation is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>At these same mutations, Sec incorporation will be completely eliminated (Figure 7).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Binding of GntR to the operators is eliminated by gluconate and also by 6-phosphogluconate.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Binding of GntR to the operators was eliminated by gluconate and also by 6-phosphogluconate.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Eliminating all three sites or mimicking activating phosphorylation sites is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Eliminating any deleterious effects or mimicking activating phosphorylation sites is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">any deleterious effects</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>For eliminating all three sites that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>For eliminating the inhibitory phosphorylation that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>In gel shift assay, A 6-bp insertion eliminated repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>In gel shift assay, A 6-bp insertion eliminates repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>In gel shift assay, A 6-bp insertion has eliminated repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>In gel shift assay, A 6-bp insertion will eliminate repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>In gel shift assay, Mutation of T491 eliminated the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>In gel shift assay, Mutation of T491 eliminates the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>In gel shift assay, Mutation of T491 has eliminated the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>In gel shift assay, Mutation of T491 will eliminate the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>In gel shift assay, a molar ratio of 5:1 eliminated binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>In gel shift assay, a molar ratio of 5:1 eliminates binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>In gel shift assay, a molar ratio of 5:1 has eliminated binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>In gel shift assay, a molar ratio of 5:1 will eliminate binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In gel shift assay, gluconate and also by 6-phosphogluconate eliminated Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In gel shift assay, gluconate and also by 6-phosphogluconate eliminates Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In gel shift assay, gluconate and also by 6-phosphogluconate has eliminated Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In gel shift assay, gluconate and also by 6-phosphogluconate will eliminate Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In gel shift assay, inhibition of any one of these molecules eliminated vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>In gel shift assay, inhibition of any one of these molecules eliminates vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>In gel shift assay, inhibition of any one of these molecules has eliminated vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>In gel shift assay, inhibition of any one of these molecules will eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>In gel shift assay, microbe-detecting receptors activating immune cells eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>In gel shift assay, microbe-detecting receptors activating immune cells eliminates the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>In gel shift assay, microbe-detecting receptors activating immune cells has eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>In gel shift assay, microbe-detecting receptors activating immune cells will eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>In gel shift assay, microbe-detecting receptors, such as CD14, that activate immune cells eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>In gel shift assay, microbe-detecting receptors, such as CD14, that activate immune cells eliminates the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>In gel shift assay, microbe-detecting receptors, such as CD14, that activate immune cells has eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>In gel shift assay, microbe-detecting receptors, such as CD14, that activate immune cells will eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>In gel shift assay, staurosporin (or genestein; data not shown) eliminated the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>In gel shift assay, staurosporin (or genestein; data not shown) eliminates the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>In gel shift assay, staurosporin (or genestein; data not shown) has eliminated the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>In gel shift assay, staurosporin (or genestein; data not shown) will eliminate the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>In gel shift assay, these same mutations eliminated Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>In gel shift assay, these same mutations eliminates Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>In gel shift assay, these same mutations has eliminated Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>In gel shift assay, these same mutations will eliminate Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Mutation of T491 at a 10-fold-higher concentration eliminate the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Mutation of T491 at a 10-fold-higher concentration eliminated the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Mutation of T491 located within O2 or between OT and O1 eliminated the recognition by the anti-pT598 antibody, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Mutation of T491 located within O2 or between OT and O1 eliminates the recognition by the anti-pT598 antibody, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Mutation of T491 located within O2 or between OT and O1 has eliminated the recognition by the anti-pT598 antibody, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Mutation of T491 located within O2 or between OT and O1 will eliminate the recognition by the anti-pT598 antibody, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Mutation of T491 which eliminated the recognition by the anti-pT598 antibody was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Mutation of T491 which eliminates the recognition by the anti-pT598 antibody is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>One mutation is able to eliminate the BamHI site in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Sec incorporation has been eliminated by these same mutations at a 10-fold-higher concentration.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Sec incorporation is eliminated by these same mutations at a 10-fold-higher concentration.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Sec incorporation is eliminated by these same mutations.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Sec incorporation was eliminated by these same mutations at a 10-fold-higher concentration.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Sec incorporation was eliminated by these same mutations.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Sec incorporation will be eliminated by these same mutations at a 10-fold-higher concentration.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, A 6-bp insertion can completely eliminate repression of the glpTQ promoter (Lesoon et al., 1997).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, A 6-bp insertion completely eliminate repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, A 6-bp insertion completely eliminated repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, Binding of GntR to the operators is completely eliminated by gluconate and also by 6-phosphogluconate.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, Binding of GntR to the operators was completely eliminated by gluconate and also by 6-phosphogluconate.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, Mutation of T491 can completely eliminate the recognition by the anti-pT598 antibody (Lesoon et al., 1997).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, Mutation of T491 completely eliminate the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, Mutation of T491 completely eliminated the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a molar ratio of 5:1 can completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a molar ratio of 5:1 completely eliminate binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a molar ratio of 5:1 completely eliminated binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, anti-ref1 antibody can completely eliminate formation of the nCaRE-protein complex (Lesoon et al., 1997).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, anti-ref1 antibody completely eliminate formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, anti-ref1 antibody completely eliminated formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding is completely eliminated by a molar ratio of 5:1.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding was completely eliminated by a molar ratio of 5:1.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, formation of the nCaRE-protein complex is completely eliminated by anti-ref1 antibody.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, formation of the nCaRE-protein complex was completely eliminated by anti-ref1 antibody.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, gluconate and also by 6-phosphogluconate can completely eliminate Binding of GntR to the operators (Lesoon et al., 1997).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, gluconate and also by 6-phosphogluconate completely eliminate Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, gluconate and also by 6-phosphogluconate completely eliminated Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, inhibition of any one of these molecules can completely eliminate vital stem cells (Lesoon et al., 1997).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, inhibition of any one of these molecules completely eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, inhibition of any one of these molecules completely eliminated vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, microbe-detecting receptors activating immune cells can completely eliminate the pathogens (Lesoon et al., 1997).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, microbe-detecting receptors activating immune cells completely eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, microbe-detecting receptors activating immune cells completely eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, microbe-detecting receptors, such as CD14, that activate immune cells can completely eliminate the pathogens (Lesoon et al., 1997).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, microbe-detecting receptors, such as CD14, that activate immune cells completely eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, microbe-detecting receptors, such as CD14, that activate immune cells completely eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, repression of the glpTQ promoter is completely eliminated by A 6-bp insertion.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, repression of the glpTQ promoter was completely eliminated by A 6-bp insertion.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, staurosporin (or genestein; data not shown) can completely eliminate the stabilization seen with MG132 (Lesoon et al., 1997).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, staurosporin (or genestein; data not shown) completely eliminate the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, staurosporin (or genestein; data not shown) completely eliminated the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the pathogens is completely eliminated by microbe-detecting receptors activating immune cells.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the pathogens is completely eliminated by microbe-detecting receptors, such as CD14, that activate immune cells.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the pathogens was completely eliminated by microbe-detecting receptors activating immune cells.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the pathogens was completely eliminated by microbe-detecting receptors, such as CD14, that activate immune cells.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the recognition by the anti-pT598 antibody is completely eliminated by Mutation of T491.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the recognition by the anti-pT598 antibody was completely eliminated by Mutation of T491.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the stabilization seen with MG132 is completely eliminated by staurosporin (or genestein; data not shown).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the stabilization seen with MG132 was completely eliminated by staurosporin (or genestein; data not shown).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, vital stem cells is completely eliminated by inhibition of any one of these molecules.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, vital stem cells was completely eliminated by inhibition of any one of these molecules.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet A 6-bp insertion completely eliminate repression of the glpTQ promoter (Lesoon et al., 1997).</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet Mutation of T491 completely eliminate the recognition by the anti-pT598 antibody (Lesoon et al., 1997).</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet a molar ratio of 5:1 completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet anti-ref1 antibody completely eliminate formation of the nCaRE-protein complex (Lesoon et al., 1997).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet gluconate and also by 6-phosphogluconate completely eliminate Binding of GntR to the operators (Lesoon et al., 1997).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet inhibition of any one of these molecules completely eliminate vital stem cells (Lesoon et al., 1997).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet microbe-detecting receptors activating immune cells completely eliminate the pathogens (Lesoon et al., 1997).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet microbe-detecting receptors, such as CD14, that activate immune cells completely eliminate the pathogens (Lesoon et al., 1997).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet staurosporin (or genestein; data not shown) completely eliminate the stabilization seen with MG132 (Lesoon et al., 1997).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>The same high level of activation of B-Raf occurs only when any deleterious effects are eliminated.</text>
                    <arg n="1">any deleterious effects</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>The same high level of activation of B-Raf occurs only when any deleterious effects were eliminated.</text>
                    <arg n="1">any deleterious effects</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>The same high level of activation of B-Raf occurs only when the inhibitory phosphorylation are eliminated.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>The same high level of activation of B-Raf occurs only when the inhibitory phosphorylation were eliminated.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>They establish that A 6-bp insertion, as may occur following caspase activation, can eliminate repression of the glpTQ promoter required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>They establish that A 6-bp insertion, as may occur following caspase activation, could eliminate repression of the glpTQ promoter required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>They establish that Mutation of T491, as may occur following caspase activation, can eliminate the recognition by the anti-pT598 antibody required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>They establish that Mutation of T491, as may occur following caspase activation, could eliminate the recognition by the anti-pT598 antibody required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>They establish that a molar ratio of 5:1, as may occur following caspase activation, can eliminate binding required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>They establish that a molar ratio of 5:1, as may occur following caspase activation, could eliminate binding required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>They establish that anti-ref1 antibody, as may occur following caspase activation, can eliminate formation of the nCaRE-protein complex required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>They establish that anti-ref1 antibody, as may occur following caspase activation, could eliminate formation of the nCaRE-protein complex required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>They establish that gluconate and also by 6-phosphogluconate, as may occur following caspase activation, can eliminate Binding of GntR to the operators required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>They establish that gluconate and also by 6-phosphogluconate, as may occur following caspase activation, could eliminate Binding of GntR to the operators required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>They establish that microbe-detecting receptors activating immune cells, as may occur following caspase activation, can eliminate the pathogens required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>They establish that microbe-detecting receptors activating immune cells, as may occur following caspase activation, could eliminate the pathogens required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>They establish that microbe-detecting receptors, such as CD14, that activate immune cells, as may occur following caspase activation, can eliminate the pathogens required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>They establish that microbe-detecting receptors, such as CD14, that activate immune cells, as may occur following caspase activation, could eliminate the pathogens required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>They establish that staurosporin (or genestein; data not shown), as may occur following caspase activation, can eliminate the stabilization seen with MG132 required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>They establish that staurosporin (or genestein; data not shown), as may occur following caspase activation, could eliminate the stabilization seen with MG132 required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>They establish that these same mutations, as may occur following caspase activation, can eliminate Sec incorporation required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>They establish that these same mutations, as may occur following caspase activation, could eliminate Sec incorporation required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>This occurs by A 6-bp insertion for eliminating repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>This occurs by A 6-bp insertion to eliminate repression of the glpTQ promoter.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>This occurs by Mutation of T491 for eliminating the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>This occurs by Mutation of T491 to eliminate the recognition by the anti-pT598 antibody.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>This occurs by a molar ratio of 5:1 for eliminating binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>This occurs by a molar ratio of 5:1 to eliminate binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>This occurs by anti-ref1 antibody for eliminating formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>This occurs by anti-ref1 antibody to eliminate formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>This occurs by gluconate and also by 6-phosphogluconate for eliminating Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>This occurs by gluconate and also by 6-phosphogluconate to eliminate Binding of GntR to the operators.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>This occurs by inhibition of any one of these molecules for eliminating vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>This occurs by inhibition of any one of these molecules to eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>This occurs by microbe-detecting receptors activating immune cells for eliminating the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>This occurs by staurosporin (or genestein; data not shown) for eliminating the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>This occurs by staurosporin (or genestein; data not shown) to eliminate the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>This occurs by these same mutations for eliminating Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>This occurs by these same mutations to eliminate Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>To eliminate all three sites that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">all three sites</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>To eliminate any deleterious effects make the same high level of activation of B-Raf occurs.</text>
                    <arg n="1">any deleterious effects</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>To eliminate the inhibitory phosphorylation make the same high level of activation of B-Raf occurs.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>To eliminate the inhibitory phosphorylation that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">the inhibitory phosphorylation</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>a molar ratio of 5:1 at a 10-fold-higher concentration eliminate binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>a molar ratio of 5:1 at a 10-fold-higher concentration eliminated binding.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>a molar ratio of 5:1 can eliminate binding while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>a molar ratio of 5:1 eliminated binding while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>a molar ratio of 5:1 eliminates binding while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>a molar ratio of 5:1 has eliminated binding while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>a molar ratio of 5:1 located within O2 or between OT and O1 eliminated binding, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>a molar ratio of 5:1 located within O2 or between OT and O1 eliminates binding, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>a molar ratio of 5:1 located within O2 or between OT and O1 has eliminated binding, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>a molar ratio of 5:1 located within O2 or between OT and O1 will eliminate binding, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>a molar ratio of 5:1 which eliminated binding was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>a molar ratio of 5:1 which eliminates binding is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>anti-ref1 antibody at a 10-fold-higher concentration eliminate formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>anti-ref1 antibody at a 10-fold-higher concentration eliminated formation of the nCaRE-protein complex.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>anti-ref1 antibody can eliminate formation of the nCaRE-protein complex while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>anti-ref1 antibody eliminated formation of the nCaRE-protein complex while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>anti-ref1 antibody eliminates formation of the nCaRE-protein complex while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>anti-ref1 antibody has eliminated formation of the nCaRE-protein complex while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>anti-ref1 antibody located within O2 or between OT and O1 eliminated formation of the nCaRE-protein complex, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>anti-ref1 antibody located within O2 or between OT and O1 eliminates formation of the nCaRE-protein complex, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>anti-ref1 antibody located within O2 or between OT and O1 has eliminated formation of the nCaRE-protein complex, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>anti-ref1 antibody located within O2 or between OT and O1 will eliminate formation of the nCaRE-protein complex, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>anti-ref1 antibody which eliminated formation of the nCaRE-protein complex was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>anti-ref1 antibody which eliminates formation of the nCaRE-protein complex is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>binding has been eliminated by a molar ratio of 5:1 at a 10-fold-higher concentration.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>binding is eliminated by a molar ratio of 5:1 at a 10-fold-higher concentration.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>binding is eliminated by a molar ratio of 5:1.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>binding was eliminated by a molar ratio of 5:1 at a 10-fold-higher concentration.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>binding was eliminated by a molar ratio of 5:1.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>binding will be eliminated by a molar ratio of 5:1 at a 10-fold-higher concentration.</text>
                    <arg n="0">a molar ratio of 5:1</arg>
                    <arg n="1">binding</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>formation of the nCaRE-protein complex has been eliminated by anti-ref1 antibody at a 10-fold-higher concentration.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>formation of the nCaRE-protein complex is eliminated by anti-ref1 antibody at a 10-fold-higher concentration.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>formation of the nCaRE-protein complex was eliminated by anti-ref1 antibody at a 10-fold-higher concentration.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>formation of the nCaRE-protein complex will be eliminated by anti-ref1 antibody at a 10-fold-higher concentration.</text>
                    <arg n="0">anti-ref1 antibody</arg>
                    <arg n="1">formation of the nCaRE-protein complex</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>gluconate and also by 6-phosphogluconate can eliminate Binding of GntR to the operators while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>gluconate and also by 6-phosphogluconate eliminated Binding of GntR to the operators while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>gluconate and also by 6-phosphogluconate eliminates Binding of GntR to the operators while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>gluconate and also by 6-phosphogluconate has eliminated Binding of GntR to the operators while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>gluconate and also by 6-phosphogluconate located within O2 or between OT and O1 eliminated Binding of GntR to the operators, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>gluconate and also by 6-phosphogluconate located within O2 or between OT and O1 eliminates Binding of GntR to the operators, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>gluconate and also by 6-phosphogluconate located within O2 or between OT and O1 has eliminated Binding of GntR to the operators, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>gluconate and also by 6-phosphogluconate located within O2 or between OT and O1 will eliminate Binding of GntR to the operators, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>gluconate and also by 6-phosphogluconate which eliminated Binding of GntR to the operators was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>gluconate and also by 6-phosphogluconate which eliminates Binding of GntR to the operators is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">gluconate and also by 6-phosphogluconate</arg>
                    <arg n="1">Binding of GntR to the operators</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>inhibition of any one of these molecules at a 10-fold-higher concentration eliminate vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>inhibition of any one of these molecules at a 10-fold-higher concentration eliminated vital stem cells.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>inhibition of any one of these molecules can eliminate vital stem cells while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>inhibition of any one of these molecules eliminated vital stem cells while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>inhibition of any one of these molecules eliminates vital stem cells while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>inhibition of any one of these molecules has eliminated vital stem cells while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>inhibition of any one of these molecules located within O2 or between OT and O1 eliminated vital stem cells, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>inhibition of any one of these molecules located within O2 or between OT and O1 eliminates vital stem cells, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>inhibition of any one of these molecules located within O2 or between OT and O1 has eliminated vital stem cells, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>inhibition of any one of these molecules located within O2 or between OT and O1 will eliminate vital stem cells, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>inhibition of any one of these molecules which eliminated vital stem cells was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>inhibition of any one of these molecules which eliminates vital stem cells is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>microbe-detecting receptors activating immune cells at a 10-fold-higher concentration eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>microbe-detecting receptors activating immune cells at a 10-fold-higher concentration eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>microbe-detecting receptors activating immune cells can eliminate the pathogens while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>microbe-detecting receptors activating immune cells eliminated the pathogens while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>microbe-detecting receptors activating immune cells eliminates the pathogens while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>microbe-detecting receptors activating immune cells has eliminated the pathogens while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>microbe-detecting receptors activating immune cells located within O2 or between OT and O1 eliminated the pathogens, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>microbe-detecting receptors activating immune cells located within O2 or between OT and O1 eliminates the pathogens, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>microbe-detecting receptors activating immune cells located within O2 or between OT and O1 has eliminated the pathogens, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>microbe-detecting receptors activating immune cells located within O2 or between OT and O1 will eliminate the pathogens, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>microbe-detecting receptors activating immune cells which eliminated the pathogens was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>microbe-detecting receptors activating immune cells which eliminates the pathogens is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells at a 10-fold-higher concentration eliminate the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells at a 10-fold-higher concentration eliminated the pathogens.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells can eliminate the pathogens while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells eliminated the pathogens while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells eliminates the pathogens while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells has eliminated the pathogens while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells located within O2 or between OT and O1 eliminated the pathogens, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells located within O2 or between OT and O1 eliminates the pathogens, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells located within O2 or between OT and O1 has eliminated the pathogens, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells located within O2 or between OT and O1 will eliminate the pathogens, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells which eliminated the pathogens was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>microbe-detecting receptors, such as CD14, that activate immune cells which eliminates the pathogens is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>repression of the glpTQ promoter has been eliminated by A 6-bp insertion at a 10-fold-higher concentration.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>repression of the glpTQ promoter is eliminated by A 6-bp insertion at a 10-fold-higher concentration.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>repression of the glpTQ promoter is eliminated by A 6-bp insertion.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>repression of the glpTQ promoter was eliminated by A 6-bp insertion at a 10-fold-higher concentration.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>repression of the glpTQ promoter was eliminated by A 6-bp insertion.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>repression of the glpTQ promoter will be eliminated by A 6-bp insertion at a 10-fold-higher concentration.</text>
                    <arg n="0">A 6-bp insertion</arg>
                    <arg n="1">repression of the glpTQ promoter</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>staurosporin (or genestein; data not shown) at a 10-fold-higher concentration eliminate the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>staurosporin (or genestein; data not shown) at a 10-fold-higher concentration eliminated the stabilization seen with MG132.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>staurosporin (or genestein; data not shown) can eliminate the stabilization seen with MG132 while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>staurosporin (or genestein; data not shown) eliminated the stabilization seen with MG132 while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>staurosporin (or genestein; data not shown) eliminates the stabilization seen with MG132 while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>staurosporin (or genestein; data not shown) has eliminated the stabilization seen with MG132 while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>staurosporin (or genestein; data not shown) located within O2 or between OT and O1 eliminated the stabilization seen with MG132, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>staurosporin (or genestein; data not shown) located within O2 or between OT and O1 eliminates the stabilization seen with MG132, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>staurosporin (or genestein; data not shown) located within O2 or between OT and O1 has eliminated the stabilization seen with MG132, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>staurosporin (or genestein; data not shown) located within O2 or between OT and O1 will eliminate the stabilization seen with MG132, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>staurosporin (or genestein; data not shown) which eliminated the stabilization seen with MG132 was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>staurosporin (or genestein; data not shown) which eliminates the stabilization seen with MG132 is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>the BamHI site is eliminated by One mutation in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>the BamHI site was eliminated by One mutation in exon 7.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                    <arg n="2">exon 7</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>the other has eliminated the HindIII site in exon 11 of the phenylalanine hydroxylase gene.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                    <arg n="2">exon 11 of the phenylalanine hydroxylase gene</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>the pathogens has been eliminated by microbe-detecting receptors activating immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>the pathogens has been eliminated by microbe-detecting receptors, such as CD14, that activate immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>the pathogens is eliminated by microbe-detecting receptors activating immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>the pathogens is eliminated by microbe-detecting receptors activating immune cells.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>the pathogens is eliminated by microbe-detecting receptors, such as CD14, that activate immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>the pathogens is eliminated by microbe-detecting receptors, such as CD14, that activate immune cells.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>the pathogens was eliminated by microbe-detecting receptors activating immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>the pathogens was eliminated by microbe-detecting receptors activating immune cells.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>the pathogens was eliminated by microbe-detecting receptors, such as CD14, that activate immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>the pathogens was eliminated by microbe-detecting receptors, such as CD14, that activate immune cells.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>the pathogens will be eliminated by microbe-detecting receptors activating immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors activating immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>the pathogens will be eliminated by microbe-detecting receptors, such as CD14, that activate immune cells at a 10-fold-higher concentration.</text>
                    <arg n="0">microbe-detecting receptors, such as CD14, that activate immune cells</arg>
                    <arg n="1">the pathogens</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>the recognition by the anti-pT598 antibody has been eliminated by Mutation of T491 at a 10-fold-higher concentration.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>the recognition by the anti-pT598 antibody is eliminated by Mutation of T491 at a 10-fold-higher concentration.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>the recognition by the anti-pT598 antibody is eliminated by Mutation of T491.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>the recognition by the anti-pT598 antibody was eliminated by Mutation of T491 at a 10-fold-higher concentration.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>the recognition by the anti-pT598 antibody was eliminated by Mutation of T491.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>the recognition by the anti-pT598 antibody will be eliminated by Mutation of T491 at a 10-fold-higher concentration.</text>
                    <arg n="0">Mutation of T491</arg>
                    <arg n="1">the recognition by the anti-pT598 antibody</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>the stabilization seen with MG132 has been eliminated by staurosporin (or genestein; data not shown) at a 10-fold-higher concentration.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>the stabilization seen with MG132 is eliminated by staurosporin (or genestein; data not shown) at a 10-fold-higher concentration.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>the stabilization seen with MG132 is eliminated by staurosporin (or genestein; data not shown).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>the stabilization seen with MG132 was eliminated by staurosporin (or genestein; data not shown) at a 10-fold-higher concentration.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>the stabilization seen with MG132 was eliminated by staurosporin (or genestein; data not shown).</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>the stabilization seen with MG132 will be eliminated by staurosporin (or genestein; data not shown) at a 10-fold-higher concentration.</text>
                    <arg n="0">staurosporin (or genestein; data not shown)</arg>
                    <arg n="1">the stabilization seen with MG132</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>these same mutations at a 10-fold-higher concentration eliminate Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>these same mutations at a 10-fold-higher concentration eliminated Sec incorporation.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>these same mutations can eliminate Sec incorporation while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>these same mutations eliminated Sec incorporation while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>these same mutations eliminates Sec incorporation while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>these same mutations has eliminated Sec incorporation while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>these same mutations located within O2 or between OT and O1 eliminated Sec incorporation, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>these same mutations located within O2 or between OT and O1 eliminates Sec incorporation, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>these same mutations located within O2 or between OT and O1 has eliminated Sec incorporation, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>these same mutations located within O2 or between OT and O1 will eliminate Sec incorporation, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>these same mutations which eliminated Sec incorporation was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>these same mutations which eliminates Sec incorporation is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">these same mutations</arg>
                    <arg n="1">Sec incorporation</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>vital stem cells has been eliminated by inhibition of any one of these molecules at a 10-fold-higher concentration.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>vital stem cells is eliminated by inhibition of any one of these molecules at a 10-fold-higher concentration.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>vital stem cells is eliminated by inhibition of any one of these molecules.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>vital stem cells was eliminated by inhibition of any one of these molecules at a 10-fold-higher concentration.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>vital stem cells was eliminated by inhibition of any one of these molecules.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>vital stem cells will be eliminated by inhibition of any one of these molecules at a 10-fold-higher concentration.</text>
                    <arg n="0">inhibition of any one of these molecules</arg>
                    <arg n="1">vital stem cells</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>As illustrated in Figure 1, One mutation can not eliminate the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>As illustrated in Figure 1, One mutation did not eliminate the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>As illustrated in Figure 1, One mutation does not eliminate the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>As illustrated in Figure 1, The requirement of induction is not eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>As illustrated in Figure 1, The requirement of induction was not eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>As illustrated in Figure 1, The requirement of induction will not be eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>As illustrated in Figure 1, a 3-bp in-frame deletion can not eliminate an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>As illustrated in Figure 1, a 3-bp in-frame deletion did not eliminate an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>As illustrated in Figure 1, a 3-bp in-frame deletion does not eliminate an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>As illustrated in Figure 1, an asparagine residue is not eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>As illustrated in Figure 1, an asparagine residue was not eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>As illustrated in Figure 1, an asparagine residue will not be eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>As illustrated in Figure 1, mutation of a new locus, galS can not eliminate The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>As illustrated in Figure 1, mutation of a new locus, galS did not eliminate The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>As illustrated in Figure 1, mutation of a new locus, galS does not eliminate The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>As illustrated in Figure 1, the BamHI site is not eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>As illustrated in Figure 1, the BamHI site was not eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>As illustrated in Figure 1, the BamHI site will not be eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>As illustrated in Figure 1, the HindIII site is not eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>As illustrated in Figure 1, the HindIII site was not eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>As illustrated in Figure 1, the HindIII site will not be eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>As illustrated in Figure 1, the other can not eliminate the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>As illustrated in Figure 1, the other did not eliminate the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>As illustrated in Figure 1, the other does not eliminate the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>At One mutation, the BamHI site can be completely eliminated (Figure 7).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>At One mutation, the BamHI site is completely eliminated (Figure 7).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>At One mutation, the BamHI site is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>At One mutation, the BamHI site will be completely eliminated (Figure 7).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>At a 3-bp in-frame deletion, an asparagine residue can be completely eliminated (Figure 7).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>At a 3-bp in-frame deletion, an asparagine residue is completely eliminated (Figure 7).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>At a 3-bp in-frame deletion, an asparagine residue is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>At a 3-bp in-frame deletion, an asparagine residue will be completely eliminated (Figure 7).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>At mutation of a new locus, galS, The requirement of induction can be completely eliminated (Figure 7).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>At mutation of a new locus, galS, The requirement of induction is completely eliminated (Figure 7).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>At mutation of a new locus, galS, The requirement of induction is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>At mutation of a new locus, galS, The requirement of induction will be completely eliminated (Figure 7).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>At the other, the HindIII site can be completely eliminated (Figure 7).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>At the other, the HindIII site is completely eliminated (Figure 7).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>At the other, the HindIII site is observed to be completely eliminated (Figure 7).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>At the other, the HindIII site will be completely eliminated (Figure 7).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Eliminating exogenous H(2)O(2) or mimicking activating phosphorylation sites is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>For eliminating exogenous H(2)O(2) that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>In gel shift assay, One mutation eliminated the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>In gel shift assay, One mutation eliminates the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>In gel shift assay, One mutation has eliminated the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>In gel shift assay, One mutation will eliminate the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>In gel shift assay, a 3-bp in-frame deletion eliminated an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>In gel shift assay, a 3-bp in-frame deletion eliminates an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>In gel shift assay, a 3-bp in-frame deletion has eliminated an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>In gel shift assay, a 3-bp in-frame deletion will eliminate an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>In gel shift assay, mutation of a new locus, galS eliminated The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>In gel shift assay, mutation of a new locus, galS eliminates The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>In gel shift assay, mutation of a new locus, galS has eliminated The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>In gel shift assay, mutation of a new locus, galS will eliminate The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>In gel shift assay, the other eliminated the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>In gel shift assay, the other eliminates the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>In gel shift assay, the other has eliminated the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>In gel shift assay, the other will eliminate the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>One mutation at a 10-fold-higher concentration eliminate the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>One mutation at a 10-fold-higher concentration eliminated the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>One mutation can eliminate the BamHI site while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>One mutation eliminated the BamHI site while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>One mutation eliminates the BamHI site while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>One mutation has eliminated the BamHI site while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>One mutation located within O2 or between OT and O1 eliminated the BamHI site, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>One mutation located within O2 or between OT and O1 eliminates the BamHI site, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>One mutation located within O2 or between OT and O1 has eliminated the BamHI site, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>One mutation located within O2 or between OT and O1 will eliminate the BamHI site, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>One mutation which eliminated the BamHI site was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>One mutation which eliminates the BamHI site is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Secondly, SBP2 The requirement of induction activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding is completely eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Secondly, SBP2 The requirement of induction activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding was completely eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Secondly, SBP2 The requirement of induction activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, mutation of a new locus, galS can completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Secondly, SBP2 The requirement of induction activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, mutation of a new locus, galS completely eliminate binding.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Secondly, SBP2 The requirement of induction activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, mutation of a new locus, galS completely eliminated binding.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>Secondly, SBP2 The requirement of induction activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet mutation of a new locus, galS completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>Secondly, SBP2 an asparagine residue activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a 3-bp in-frame deletion can completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>Secondly, SBP2 an asparagine residue activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a 3-bp in-frame deletion completely eliminate binding.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>Secondly, SBP2 an asparagine residue activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a 3-bp in-frame deletion completely eliminated binding.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>Secondly, SBP2 an asparagine residue activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding is completely eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>Secondly, SBP2 an asparagine residue activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding was completely eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>Secondly, SBP2 an asparagine residue activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet a 3-bp in-frame deletion completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, One mutation can completely eliminate the BamHI site (Lesoon et al., 1997).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, One mutation completely eliminate the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, One mutation completely eliminated the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, The requirement of induction is completely eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, The requirement of induction was completely eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a 3-bp in-frame deletion can completely eliminate an asparagine residue (Lesoon et al., 1997).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a 3-bp in-frame deletion completely eliminate an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, a 3-bp in-frame deletion completely eliminated an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, an asparagine residue is completely eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, an asparagine residue was completely eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, mutation of a new locus, galS can completely eliminate The requirement of induction (Lesoon et al., 1997).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, mutation of a new locus, galS completely eliminate The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, mutation of a new locus, galS completely eliminated The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the BamHI site is completely eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the BamHI site was completely eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the HindIII site is completely eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the HindIII site was completely eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the other can completely eliminate the HindIII site (Lesoon et al., 1997).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the other completely eliminate the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the other completely eliminated the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet One mutation completely eliminate the BamHI site (Lesoon et al., 1997).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet a 3-bp in-frame deletion completely eliminate an asparagine residue (Lesoon et al., 1997).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet mutation of a new locus, galS completely eliminate The requirement of induction (Lesoon et al., 1997).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet the other completely eliminate the HindIII site (Lesoon et al., 1997).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Secondly, SBP2 the BamHI site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, One mutation can completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Secondly, SBP2 the BamHI site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, One mutation completely eliminate binding.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Secondly, SBP2 the BamHI site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, One mutation completely eliminated binding.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Secondly, SBP2 the BamHI site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding is completely eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Secondly, SBP2 the BamHI site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding was completely eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Secondly, SBP2 the BamHI site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet One mutation completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Secondly, SBP2 the HindIII site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding is completely eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Secondly, SBP2 the HindIII site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, binding was completely eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Secondly, SBP2 the HindIII site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the other can completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Secondly, SBP2 the HindIII site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the other completely eliminate binding.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Secondly, SBP2 the HindIII site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, the other completely eliminated binding.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Secondly, SBP2 the HindIII site activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet the other completely eliminate binding (Lesoon et al., 1997).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>The requirement of induction has been eliminated by mutation of a new locus, galS at a 10-fold-higher concentration.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>The requirement of induction is eliminated by mutation of a new locus, galS at a 10-fold-higher concentration.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>The requirement of induction is eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>The requirement of induction was eliminated by mutation of a new locus, galS at a 10-fold-higher concentration.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>The requirement of induction was eliminated by mutation of a new locus, galS.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>The requirement of induction will be eliminated by mutation of a new locus, galS at a 10-fold-higher concentration.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>The same high level of activation of B-Raf occurs only when exogenous H(2)O(2) are eliminated.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>The same high level of activation of B-Raf occurs only when exogenous H(2)O(2) were eliminated.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>They establish that One mutation, as may occur following caspase activation, can eliminate the BamHI site required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>They establish that One mutation, as may occur following caspase activation, could eliminate the BamHI site required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>They establish that a 3-bp in-frame deletion, as may occur following caspase activation, can eliminate an asparagine residue required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>They establish that a 3-bp in-frame deletion, as may occur following caspase activation, could eliminate an asparagine residue required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>They establish that mutation of a new locus, galS, as may occur following caspase activation, can eliminate The requirement of induction required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>They establish that mutation of a new locus, galS, as may occur following caspase activation, could eliminate The requirement of induction required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>They establish that the other, as may occur following caspase activation, can eliminate the HindIII site required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>They establish that the other, as may occur following caspase activation, could eliminate the HindIII site required for skeletal muscle regeneration during chronic catabolic conditions.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>This occurs by One mutation for eliminating the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>This occurs by One mutation to eliminate the BamHI site.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>This occurs by a 3-bp in-frame deletion for eliminating an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>This occurs by a 3-bp in-frame deletion to eliminate an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>This occurs by mutation of a new locus, galS for eliminating The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>This occurs by mutation of a new locus, galS to eliminate The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>This occurs by the other for eliminating the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>This occurs by the other to eliminate the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>To eliminate exogenous H(2)O(2) make the same high level of activation of B-Raf occurs.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>To eliminate exogenous H(2)O(2) that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.</text>
                    <arg n="1">exogenous H(2)O(2)</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>a 3-bp in-frame deletion at a 10-fold-higher concentration eliminate an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>a 3-bp in-frame deletion at a 10-fold-higher concentration eliminated an asparagine residue.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>a 3-bp in-frame deletion can eliminate an asparagine residue in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>a 3-bp in-frame deletion can eliminate an asparagine residue while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>a 3-bp in-frame deletion eliminated an asparagine residue in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>a 3-bp in-frame deletion eliminated an asparagine residue while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>a 3-bp in-frame deletion eliminates an asparagine residue in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>a 3-bp in-frame deletion eliminates an asparagine residue while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>a 3-bp in-frame deletion has eliminated an asparagine residue in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>a 3-bp in-frame deletion has eliminated an asparagine residue while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>a 3-bp in-frame deletion is able to eliminate an asparagine residue in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>a 3-bp in-frame deletion located within O2 or between OT and O1 eliminated an asparagine residue, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>a 3-bp in-frame deletion located within O2 or between OT and O1 eliminates an asparagine residue, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>a 3-bp in-frame deletion located within O2 or between OT and O1 has eliminated an asparagine residue, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>a 3-bp in-frame deletion located within O2 or between OT and O1 will eliminate an asparagine residue, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>a 3-bp in-frame deletion which eliminated an asparagine residue was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>a 3-bp in-frame deletion which eliminates an asparagine residue is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>a 3-bp in-frame deletion would eliminate an asparagine residue in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>an asparagine residue has been eliminated by a 3-bp in-frame deletion at a 10-fold-higher concentration.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>an asparagine residue is eliminated by a 3-bp in-frame deletion at a 10-fold-higher concentration.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>an asparagine residue is eliminated by a 3-bp in-frame deletion in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>an asparagine residue is eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>an asparagine residue was eliminated by a 3-bp in-frame deletion at a 10-fold-higher concentration.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>an asparagine residue was eliminated by a 3-bp in-frame deletion in a kinase domain of the product.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                    <arg n="2">a kinase domain of the product</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>an asparagine residue was eliminated by a 3-bp in-frame deletion.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>an asparagine residue will be eliminated by a 3-bp in-frame deletion at a 10-fold-higher concentration.</text>
                    <arg n="0">a 3-bp in-frame deletion</arg>
                    <arg n="1">an asparagine residue</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>mutation of a new locus, galS at a 10-fold-higher concentration eliminate The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>mutation of a new locus, galS at a 10-fold-higher concentration eliminated The requirement of induction.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>mutation of a new locus, galS can eliminate The requirement of induction while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>mutation of a new locus, galS eliminated The requirement of induction while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>mutation of a new locus, galS eliminates The requirement of induction while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>mutation of a new locus, galS has eliminated The requirement of induction while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>mutation of a new locus, galS located within O2 or between OT and O1 eliminated The requirement of induction, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>mutation of a new locus, galS located within O2 or between OT and O1 eliminates The requirement of induction, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>mutation of a new locus, galS located within O2 or between OT and O1 has eliminated The requirement of induction, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>mutation of a new locus, galS located within O2 or between OT and O1 will eliminate The requirement of induction, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>mutation of a new locus, galS which eliminated The requirement of induction was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>mutation of a new locus, galS which eliminates The requirement of induction is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">mutation of a new locus, galS</arg>
                    <arg n="1">The requirement of induction</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>the BamHI site has been eliminated by One mutation at a 10-fold-higher concentration.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>the BamHI site is eliminated by One mutation at a 10-fold-higher concentration.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>the BamHI site is eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>the BamHI site was eliminated by One mutation at a 10-fold-higher concentration.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>the BamHI site was eliminated by One mutation.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>the BamHI site will be eliminated by One mutation at a 10-fold-higher concentration.</text>
                    <arg n="0">One mutation</arg>
                    <arg n="1">the BamHI site</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>the HindIII site has been eliminated by the other at a 10-fold-higher concentration.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>the HindIII site is eliminated by the other at a 10-fold-higher concentration.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>the HindIII site is eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>the HindIII site was eliminated by the other at a 10-fold-higher concentration.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>the HindIII site was eliminated by the other.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>the HindIII site will be eliminated by the other at a 10-fold-higher concentration.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>the other at a 10-fold-higher concentration eliminate the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>the other at a 10-fold-higher concentration eliminated the HindIII site.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>the other can eliminate the HindIII site while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>the other eliminated the HindIII site while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>the other eliminates the HindIII site while mutation at S494 has no effect (Figure 2C).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>the other has eliminated the HindIII site while mutation at S494 had no effect (Figure 2C).</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>the other located within O2 or between OT and O1 eliminated the HindIII site, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>the other located within O2 or between OT and O1 eliminates the HindIII site, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>the other located within O2 or between OT and O1 has eliminated the HindIII site, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>the other located within O2 or between OT and O1 will eliminate the HindIII site, whereas significant repression will be maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>the other which eliminated the HindIII site was located within O2 or between OT and O1, whereas significant repression was maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>the other which eliminates the HindIII site is located within O2 or between OT and O1, whereas significant repression is maintained in the case of a 10-bp insertion within O2.</text>
                    <arg n="0">the other</arg>
                    <arg n="1">the HindIII site</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
